Cupping therapy for treating ankylosing spondylitis: The evidence from systematic review and meta-analysis

Abstract

ObjectiveCupping therapy has been widely used in Eastern Asia, the Middle East, or Central and North Europe to manage the symptom of ankylosing spondylitis (AS). The aim of this systematic review was to review data from randomized controlled trials (RCTs) of cupping therapy for treating patients with AS. MethodsDatabases that were searched from their inception until December 2017 included: MEDLINE, CINAHL, EMBASE, AMED, Cochrane Central Register of Controlled Trials, four Chinese databases [Chinese BioMedical Database, China National Knowledge Infrastructure, Wan-Fang Data, and the Chinese WeiPu Database], KoreaMed, The Korean National Assembly Library, Japana Centra Revuo Medicina (http://www.jamas.gr.jp/) and CiNii. In this systematic review, only RCTs that were related to the effects of cupping therapy on managing AS were included. A quantitative synthesis of RCTs will be conducted using RevMan 5.3 software. Study selection, data extraction, and validation were performed independently by two reviewers. Quantitative analysis of RCTs were performed using RevMan 5.3 software, and cochrane criteria for risk-of-bias were used to assess the methodological quality of the trials. ResultsA total of 5 RCTs met the inclusion criteria, and most were of low methodological quality. Participants in cupping therapy plus Western medicine group showed significantly greater improvements in the response rate [RR = 1.13, 95%CI (1.06, 1.22), p < 0.01] with low heterogeneity (Chi2 = 2.88, p = 0.41, I2 = 0%). Moreover, when compared with western medicine alone, meta-analysis indicated favorable statistically significant effects of cupping therapy plus western medicine on the Bath Ankylosing Spondylitis Functional Index (BASFI) [MD = -16.63, 95%CI (−17.75, −15.51), p < 0.01] and Bath Ankylosing Disease Activity Index (BASDAI) [MD = -9.93, 95%CI (−10.34, −9.52), p < 0.01], with low heterogeneity (Chi2 = 0.32, p = 0.85, I2 = 0% in BASFI; (Chi2 = 2.46, p = 0.29, I2 = 19% in BASDAI). Furthermore, when compared with western medicine alone, meta-analysis demonstrated statistically significant effects of cupping therapy plus western medicine on the serum level of ESR [MD = -1.28, 95% CI (−1.44, −1.13), p < 0.01] and the serum level of CRP [MD = −3.97, 95%CI (−4.71, −3.22), p < 0.01], with low heterogeneity (Chi2 = 0.50, p = 0.78, I2 = 0% in the serum level of ESR; Chi2 = 0.19, p = 0.91, I2 = 0% in the serum level of CRP). ConclusionTaken together, only weak evidence supported the hypothesis that cupping therapy had potential benefits for patients with AS.